458 results on '"Ingle, James N."'
Search Results
2. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer
3. Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer
4. Identification of a Notch transcriptomic signature for breast cancer
5. Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer
6. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
7. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
8. Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
9. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.
10. ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis
11. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk
12. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
13. Centrosome Hypertrophy in Human Breast Tumors: Implications for Genomic Stability and Cell Polarity
14. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1
15. Abstract P4-02-09: Evaluation of the Automated Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC-005 Prospective Trial
16. Abstract P2-11-34: Mitotic spindle hotspot counting using deep learning networks is highly associated with clinical outcomes in patients with early-stage triple-negative breast cancer who did not receive systemic therapy
17. Abstract P3-11-04: Endoxifen Downregulates AKT Phosphorylation Through Protein Kinase C Beta 1 in ER+/HER2- Breast Cancer
18. Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial
19. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
20. Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
21. Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
22. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Breast Cancer Patients
23. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
24. Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors
25. Skeletal and Uterotrophic Effects of Endoxifen in Female Rats
26. Expression of Immunomodulatory Neutrophil-activating Protein of Helicobacter pylori Enhances the Antitumor Activity of Oncolytic Measles Virus
27. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
28. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
29. Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
30. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)
31. Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies
32. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
33. Abstract P1-04-01: Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)
34. Abstract PD1-03: Estrogen receptor is a target of enzalutamide in ER+ breast cancer
35. Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation
36. Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome
37. Anastrozole regulates fatty acid synthase in breast cancer
38. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen
39. Aromatase Inhibitor-Associated Bone Fractures: A Case-Cohort GWAS and Functional Genomics
40. Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA
41. SNP biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer
42. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
43. Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)
44. A multidisciplinary approach to the management of breast cancer, Part 2: therapeutic considerations
45. A multidisciplinary approach to the management of breast cancer, Part 1: prevention and diagnosis
46. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models
47. Abstract PD7-05: Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY)
48. Abstract PS6-02: Spatially defined immune-related proteins and outcome in triple negative breast cancer in the FinXX trial and Mayo Clinic cohort
49. Abstract PD2-09: The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)
50. Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.